The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process

被引:4
|
作者
Carroll, Christopher [1 ]
Kaltenthaler, Eva [1 ]
Hill-McManus, Daniel [2 ]
Scope, Alison [1 ]
Holmes, Michael [1 ]
Rice, Stephen [3 ]
Rose, Micah [4 ]
Tappenden, Paul [1 ]
Woolacott, Nerys [5 ]
机构
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Bangor Univ, Bangor, Gwynedd, Wales
[3] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Southampton, Southampton, Hants, England
[5] Univ York, York, N Yorkshire, England
关键词
evidence review groups (ERGS); health policy; National Institute for Health and Care Excellence (NICE); single technology appraisal (STA); HEALTH; SUBMISSIONS;
D O I
10.1016/j.jval.2016.08.729
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: As part of the UK National Institute for Health and Care Excellence (NICE) single technology appraisal process, independent evidence review groups (ERGS) critically appraise a company's submission relating to a specific technology and indication. Objectives: To explore the type of additional exploratory analyses conducted by ERGS and their impact on the recommendations made by NICE. Methods: The 100 most recently completed single technology appraisals with published guidance were selected for inclusion. A content analysis of relevant documents was undertaken to identify and extract relevant data, and narrative synthesis was used to rationalize and present these data. Results: The types of exploratory analysis conducted in relation to companies' models were fixing errors, addressing violations, addressing matters of judgment, and the provision of a new, ERG-preferred base case. Ninety-three of the 100 ERG reports contained at least one of these analyses. The most frequently reported type of analysis in these 93 ERG reports related to the category "Matters of judgment," which was reported in 83 reports (89%). At least one of the exploratory analyses conducted and reported by an ERG is mentioned in 97% of NICE appraisal consultation documents and 94% of NICE final appraisal determinations, and had a clear influence on recommendations in 72% of appraisal consultation documents and 47% of final appraisal determinations. Conclusions: These results suggest that the additional analyses undertaken by ERGS in the appraisal of company submissions are highly influential in the policy-making and decision making process.
引用
收藏
页码:785 / 791
页数:7
相关论文
共 50 条
  • [31] Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Sabine E. Grimm
    Nigel Armstrong
    Bram L. T. Ramaekers
    Xavier Pouwels
    Shona Lang
    Svenja Petersohn
    Rob Riemsma
    Gillian Worthy
    Lisa Stirk
    Janine Ross
    Jos Kleijnen
    Manuela A. Joore
    PharmacoEconomics, 2019, 37 : 655 - 667
  • [32] Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Carroll, Christopher
    Tappenden, Paul
    Rafia, Rachid
    Hamilton, Jean
    Chambers, Duncan
    Clowes, Mark
    Durrington, Paul
    Qureshi, Nadeem
    Wierzbicki, Anthony S.
    PHARMACOECONOMICS, 2017, 35 (05) : 537 - 547
  • [33] Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Paul Tappenden
    Christopher Carroll
    John Stevens
    Emma Simpson
    Praveen Thokala
    Ruth Wong
    Josh Wright
    Rebecca Auer
    PharmacoEconomics, 2019, 37 : 7 - 18
  • [34] Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Grimm, Sabine E.
    Armstrong, Nigel
    Ramaekers, Bram L. T.
    Pouwels, Xavier
    Lang, Shona
    Petersohn, Svenja
    Riemsma, Rob
    Worthy, Gillian
    Stirk, Lisa
    Ross, Janine
    Kleijnen, Jos
    Joore, Manuela A.
    PHARMACOECONOMICS, 2019, 37 (05) : 655 - 667
  • [35] Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Ramaekers, Bram L. T.
    Riemsma, Rob
    Grimm, Sabine
    Fayter, Debra
    Deshpande, Sohan
    Armstrong, Nigel
    Witlox, Willem
    Pouwels, Xavier
    Duffy, Steven
    Worthy, Gill
    Kleijnen, Jos
    Joore, Manuela A.
    PHARMACOECONOMICS, 2019, 37 (07) : 887 - 894
  • [36] Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Bram L. T. Ramaekers
    Rob Riemsma
    Sabine Grimm
    Debra Fayter
    Sohan Deshpande
    Nigel Armstrong
    Willem Witlox
    Xavier Pouwels
    Steven Duffy
    Gill Worthy
    Jos Kleijnen
    Manuela A. Joore
    PharmacoEconomics, 2019, 37 : 887 - 894
  • [37] Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Hema Mistry
    Chidozie Nduka
    Martin Connock
    Jill Colquitt
    Theodoros Mantopoulos
    Emma Loveman
    Renata Walewska
    James Mason
    PharmacoEconomics, 2019, 37 : 869 - 869
  • [38] Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Christopher Carroll
    Paul Tappenden
    Rachid Rafia
    Jean Hamilton
    Duncan Chambers
    Mark Clowes
    Paul Durrington
    Nadeem Qureshi
    Anthony S. Wierzbicki
    PharmacoEconomics, 2017, 35 : 537 - 547
  • [39] Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Stevenson, Matt
    Pandor, Abdullah
    Stevens, John W.
    Rawdin, Andrew
    Rice, Peter
    Thompson, Jez
    Morgan, Marsha Y.
    PHARMACOECONOMICS, 2015, 33 (08) : 833 - 847
  • [40] Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Bram L. T. Ramaekers
    Robert Wolff
    Anoukh van Giessen
    Xavier Pouwels
    Debra Fayter
    Shona Lang
    Nigel Armstrong
    Gill Worthy
    Steven Duffy
    Jos Kleijnen
    Manuela A. Joore
    PharmacoEconomics, 2018, 36 : 285 - 288